Optimizing BTK Inhibitor Treatment in CLL: Dose Reduction Impact | Kerry Rogers, MD | ASH 2023

Lenalidomide Early Intervention in High-Risk CLL | Kerry Rogers, MD | ASH 2023

Second Generation CLL Treatment: Zanubrutinib + Sonrotoclax | Constantine Tam, MD, MBBS | ASH 2023

Optimizing CLL Treatment: BTK Resistance and Dual Therapy | Kerry Rogers, MD | ASH 2023

ALPINE Trial: Zanubrutinib vs Ibrutinib in Treating CLL | Constantine Tam, MD, MBBS | ASH 2023

Richter's Transformation & CAR T Therapy in CLL | Adam Kittai, MD | ASH 2023

A Multicenter, Retrospective Analysis of AML Patients | Jan Bewersdorf, MD | ASH 2023

Investigating Prognostic Significance of Malnutrition in AML | Samuel Yates, MD, MS | ASH 2023

Telehealth Program for Older Patients & Decision Preferences in AML | Jane Liesveld, MD | ASH 2023

ABBV-525 in CLL and Non-Hodgkin Lymphoma Patients | Meghan Thompson, MD | ASH 2023

IDH2 Mutation Allows Myeloid Differentiation | Jane Liesveld, MD | ASH 2023